|
1
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic
strategies. Nat Rev Clin Oncol. 15:95–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cereda S, Passoni P, Reni M, Viganò MG,
Aldrighetti L, Nicoletti R and Villa E: The cisplatin, epirubicin,
5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary
tract adenocarcinoma. Cancer. 116:2208–2214. 2010.PubMed/NCBI
|
|
4
|
Cheng W, Yang Z, Wang S, Li Y, Wei H, Tian
X and Kan Q: Recent development of CDK inhibitors: An overview of
CDK/inhibitor co-crystal structures. Eur J Med Chem. 64:615–639.
2019. View Article : Google Scholar
|
|
5
|
Schwartz GK and Shah MA: Targeting the
cell cycle: A new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deep G and Agarwal R: New combination
therapies with cell cycle agents. Curr Opin Investig Drugs.
9:591–604. 2008.PubMed/NCBI
|
|
7
|
Coxon CR, Anscombe E, Harnor SJ, Martin
MP, Carbain B, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S,
Matheson CJ, et al: Cyclin-dependent kinase (CDK) inhibitors:
Structure-activity relationships and insights into the CDK-2
selectivity of 6-substituted 2-arylaminopurines. J Med Chem.
60:1746–1767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M,
Liu S, Jiang X, Zheng J, Zhang X, et al: Prognostic biomarker
identification through integrating the gene signatures of
hepatocellular carcinoma properties. EbioMedicine. 19:18–30. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su
TC, Huang RH, Wen CK, Chen CY, Chen CJ, et al: High
nuclear/cytoplasmic ratio of Cdk1 expression predicts poor
prognosis in colorectal cancer patients. BMC Cancer. 14:9512014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hongo F, Takaha N, Oishi M, Ueda T,
Nakamura T, Naitoh Y, Naya Y, Kamoi K, Okihara K, Matsushima T, et
al: CDK1 and CDK2 activity is a strong predictor of renal cell
carcinoma recurrence. Urol Oncol. 32:1240–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi YX, Zhu T, Zou T, Zhuo W, Chen YX,
Huang MS, Zheng W, Wang CJ, Li X, Mao XY, et al: Prognostic and
predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
Oncotarget. 7:85235–85243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang C, Elkahloun AG, Robertson M, Gills
JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC,
Travis WD, et al: Loss of cytoplasmic CDK1 predicts poor survival
in human lung cancer and confers chemotherapeutic resistance. PLoS
One. 6:e238492011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
García-Reyes B, Kretz AL Ruff JP, von
Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D and Lemke
J: The emerging role of cyclin-dependent kinases (CDKs) in
pancreatic ductal adenocarcinoma. Int J Mol Sci. 19(pii):
E32192018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feldmann G, Mishra A, Bisht S, Karikari C,
Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H,
Fendrich V, et al: Cyclin-dependent kinase inhibitor Dinaciclib
(SCH727965) inhibits pancreatic cancer growth and progression in
murine xenograft models. Cancer Biol Ther. 12:598–609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Whittaker SR, Mallinger A, Workman P and
Clarke PA: Inhibitors of cyclin-dependent kinases as cancer
therapeutics. Pharmacol Ther. 173:83–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Costa-Cabral S, Brough R, Konde A, Aarts
M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord
CJ, et al: CDK1 is a synthetic lethal target for KRAS mutant
tumours. PLoS One. 11:e01490992016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Churi CR, Shroff R, Wang Y, Rashid A, Kang
HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, et al:
Mutation profiling in cholangiocarcinoma: Prognostic and
therapeutic implications. PLoS One. 9:e1153832014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura H, Arai Y, Totoki Y, Shirota T,
Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et
al: Genomic spectra of biliary tract cancer. Nat Genet.
47:1003–1010. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mertens JC, Rizvi S and Gores GJ:
Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis.
1864:1454–1460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He W, Wang B, Zhuang Y, Shao D, Sun K and
Chen J: Berberine inhibits growth and induces G1 arrest and
apoptosis in human cholangiocarcinoma QBC939 cells. J Pharmacol
Sci. 119:341–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng J, Li Q, Wang W, Wang Y, Fu X, Wang
W, Fan L and Yan W: Apoptosis-related protein-1 acts as a tumor
suppressor in cholangiocarcinoma cells by inducing cell cycle
arrest via downregulation of cyclin-dependent kinase subunits.
Oncol Rep. 35:809–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Samukawa E, Fujihara S, Oura K, Iwama H,
Yamana Y, Tadokoro T, Chiyo T, Kobayashi K, Morishita A, Nakahara
M, et al: Angiotensin receptor blocker telmisartan inhibits cell
proliferation and tumor growth of cholangiocarcinoma through cell
cycle arrest. Int J Oncol. 51:1674–1684. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boueroy P, Aukkanimart R, Boonmars T,
Sriraj P, Ratanasuwan P, Juasook A, Wonkchalee N, Vaeteewoottacharn
K and Wongkham S: Inhibitory effect of aspirin on
cholangiocarcinoma cells. Asian Pac J Cancer Prev. 18:3091–3096.
2017.PubMed/NCBI
|
|
24
|
Sugawara H, Yasoshima M, Katayanagi K,
Kono N, Watanabe Y, Harada K and Nakanuma Y: Relationship between
interleukin-6 and proliferation and differentiation in
cholangiocarcinoma. Histopathology. 33:145–153. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tirado OM, Mateo-Lozano S and Notario V:
Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma
family tumor cells in vitro and in vivo. Cancer Res. 65:9320–9327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brierley JD, Gospodarowics MK and
Wittekind C: International union against cancer (UICC)TNM
Classification of Malignant Tumors. 8th. New York: John Wiley and
Sons, LTD.; 2017
|
|
27
|
Salaun P, Rannou Y and Prigent C: Cdk1,
Plks, Auroras, and Neks: The mitotic bodyguards. Adv Exp Med Biol.
617:41–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gavet O and Pines J: Progressive
activation of cyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell.
18:533–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gavet O and Pines J: Activation of cyclin
B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at
mitosis. J Cell Biol. 189:247–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Keenan SM, Bellone C and Baldassare JJ:
Cyclin-dependent kinase 2 nucleocytoplasmic translocation is
regulated by extracellular regulated kinase. J Biol Chem.
276:22404–22409. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Won KA and Reed SI: Activation of cyclin
E/CDK2 is coupled to site-specific autophosphorylation and
ubiquitin-dependent degradation of cyclin E. EMBO J. 15:4182–4193.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parry D, Guzi T, Shanahan F, Davis N,
Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R,
et al: Dinaciclib (SCH 727965), a novel and potent cyclin-dependent
kinase inhibitor. Mol Cancer Ther. 9:2344–2353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei D, Parsels LA, Karnak D, Davis MA,
Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y, et al:
Inhibition of protein phosphatase 2A radiosensitizes pancreatic
cancers by modulating CDC25C/CDK1 and homologous recombination
repair. Clin Cancer Res. 19:4422–4432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nilubol N, Boufraqech M, Zhang L, Gaskins
K, Shen M, Zhang YQ, Gara SK, Austin CP and Kebebew E: Synergistic
combination of flavopiridol and carfilzomib targets commonly
dysregulated pathways in adrenocortical carcinoma and has
biomarkers of response. Oncotarget. 9:33030–33042. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coley HM, Shotton CF and Thomas H:
Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic
agents in human uterine sarcoma cell lines. Anticancer Res.
27:273–278. 2007.PubMed/NCBI
|
|
36
|
Wesierska-Gadek J, Borza A, Komina O and
Maurer M: Impact of roscovitine, a selective CDK inhibitor, on
cancer cells: Bi-functionality increases its therapeutic potential.
Acta Biochim Pol. 56:495–501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nair BC, Vallabhaneni S, Tekmal RR and
Vadlamudi RK: Roscovitine confers tumor suppressive effect on
therapy-resistant breast tumor cells. Breast Cancer Res.
13:R802011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cicenas J, Kalyan K, Sorokinas A,
Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A and
Valius M: Roscovitine in cancer and other diseases. Ann Transl Med.
3:1352015.PubMed/NCBI
|
|
39
|
Bukanov NO, Moreno SE, Natoli TA, Rogers
KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L and
Ibraghimov-Beskrovnaya O: CDK inhibitors R-roscovitine and S-CR8
effectively block renal and hepatic cystogenesis in an orthologous
model of ADPKD. Cell Cycle. 11:4040–4046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin X, Yang C, Fan P, Xiao J, Zhang W,
Zhan S, Liu T, Wang D and Wu H: CDK5/FBW7-dependent ubiquitination
and degradation of EZH2 inhibits pancreatic cancer cell migration
and invasion. J Biol Chem. 292:6269–6280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Appleyard MV, O'Neill MA, Murray KE,
Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP and Thompson
AM: Seliciclib (CYC202, R-roscovitine) enhances the antitumor
effect of doxorubicin in vivo in a breast cancer xenograft model.
Int J Cancer. 124:465–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saijyo S, Kudo T, Suzuki M, Katayose Y,
Shinoda M, Muto T, Fukuhara K, Suzuki T and Matsuno S:
Establishment of a new extrahepatic bile duct carcinoma cell line,
TFK-1. Tohoku J Exp Med. 177:61–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoshikawa D, Ojima H, Kokubu A, Ochiya T,
Kasai S, Hirohashi S and Shibata T: Vandetanib (ZD6474), an
inhibitor of VEGFR and EGFR signalling, as a novel
molecular-targeted therapy against cholangiocarcinoma. Br J Cancer.
100:1257–1266. 2009. View Article : Google Scholar : PubMed/NCBI
|
